Primary systemic carnitine deficiency (PSCD) is an autosomal recessive inherited disorder of the carnitine cycle. It is caused by pathogenic variants in the SLC22A5 gene, which reduce the function of the OCTN2 transporter. This leads to very low levels of carnitine in plasma and tissues, compromising energy production from fatty acids, especially in the heart, skeletal muscle, and liver.
Systemic primary carnitine deficiency
The SLC22A5 gene encodes the OCTN2 transporter (Organic Cation Transporter Novel 2), responsible for introducing L-carnitine into cells and reabsorbing it in the kidney to prevent urinary loss. This function is particularly important in tissues with high energy demands, such as the heart, skeletal muscle, liver, and kidneys.
Carnitine allows the transport of long-chain fatty acids into the mitochondria, where they are oxidized to produce energy. When pathogenic biallelic variants exist in SLC22A5, the transporter functions poorly or is absent, carnitine is lost via the kidneys, and its availability in tissues is markedly reduced. Consequently, the body cannot utilize fats well during fasting or infections, which favors hypoketotic hypoglycemia, myopathy, and cardiomyopathy. DSP is inherited in an autosomal recessive pattern. Its incidence varies between populations and newborn screening programs; it is particularly common in the Faroe Islands, and high frequencies have also been described in some regions of Asia due to recurrent or founder variants.
Symptoms
The clinical presentation is variable. In infants and young children, metabolic crises triggered by fasting or infections may appear, with poor feeding, lethargy, irritability, hepatomegaly, elevated transaminases, hyperammonemia, and hypoketotic hypoglycemia. In childhood, it can also present with myopathy, muscle weakness, increased creatine kinase, and dilated cardiomyopathy, which can cause arrhythmias or sudden death if untreated. Some adults present with fatigue, arrhythmias, or remain asymptomatic, and may be identified after neonatal screening of a child with low carnitine.
Disease management
Management is very effective when initiated early. The main treatment is chronic oral supplementation with L-carnitine, adjusted according to plasma levels and tolerance, to restore carnitine availability and prevent irreversible cardiac, muscular, and metabolic damage. Furthermore, it is recommended to avoid prolonged fasting, ensure carbohydrate intake during illnesses or procedures, and administer intravenous glucose if oral intake is not tolerated. Monitoring includes checks of plasma carnitine, growth and development, transaminases, creatine kinase, and periodic cardiological evaluation with ECG and echocardiogram.
Genes analyzed
Bibliography
Chen Y, Lin Q, Zeng Y, et al. Gene spectrum and clinical traits of 10 patients with primary carnitine deficiency. Mol Genet Genomic Med. 2021 Feb;9(2):e1583.
Crefcoeur LL, Visser G, Ferdinandusse S, et al. Clinical characteristics of primary carnitine deficiency: A structured review using a case-by-case approach. J Inherit Metab Dis. 2022 May;45(3):386-405.
El-Hattab AW, Scaglia F. Disorders of carnitine biosynthesis and transport. Mol Genet Metab. 2015 Nov;116(3):107-12.
Lin Y, Lin B, Chen Y, et al. Biochemical and genetic characteristics of patients with primary carnitine deficiency identified through newborn screening. Orphanet J Rare Dis. 2021 Dec 4;16(1):503.
Rasmussen J, Nielsen OW, Janzen N, et al. Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands. J Inherit Metab Dis. 2014 Mar;37(2):215-22.
